<p>梅多布魯克財富管理公司在第三季度購買了雅培（NYSE:ABT - 免費報告）的一項新股份，根據該公司在最近向證券交易委員會提交的 13F 表格。該基金購買了 9,270 股該醫療產品製造商的股票，價值約為 1,242,000 美元。雅培在梅多布魯克財富管理公司的投資組合中佔約 1.3%，使其成為該公司第 19 大持倉。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超預期後的新底部</li>
</ul>
<p>其他對沖基金最近也調整了對該公司的持股。IMG Wealth Management Inc. 在第二季度將其在雅培的股份增加了 759.1%。IMG Wealth Management Inc. 目前擁有 189 股該醫療產品製造商的股票，價值 26,000 美元，此前在該期間又購買了 167 股。Anfield Capital Management LLC 在第二季度將其在雅培的持股增加了 81.3%。Anfield Capital Management LLC 目前擁有 232 股該醫療產品製造商的股票，價值 32,000 美元，此前在上個季度又收購了 104 股。Delos Wealth Advisors LLC 在第二季度收購了雅培的新股份，價值 32,000 美元。Curio Wealth LLC 在第二季度將其在雅培的持倉增加了 15,250.0%。Curio Wealth LLC 目前擁有 307 股該醫療產品製造商的股票，價值 42,000 美元，此前在該期間又購買了 305 股。最後，Pineridge Advisors LLC 在第二季度將其在雅培的持倉增加了 34.6%。Pineridge Advisors LLC 目前擁有 315 股該醫療產品製造商的股票，價值 43,000 美元，此前在該期間又購買了 81 股。75.18% 的股票由機構投資者和對沖基金持有。</p>
<h2>雅培股票上漲 0.3%</h2>
<p>NYSE:ABT 週五開盤價為 125.45 美元。該公司的 50 日移動平均線為 126.77 美元，200 日移動平均線為 130.27 美元。該公司的市值為 2181.3 億美元，市盈率為 15.72，市盈增長比率為 2.28，貝塔值為 0.72。雅培的 12 個月低點為 110.86 美元，12 個月高點為 141.23 美元。該公司的債務與股本比率為 0.23，流動比率為 1.70，速動比率為 1.24。</p>
<ul>
<li>雅培十月股價暴跌是買入信號</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）最近於 10 月 15 日發佈了其財報。該醫療產品製造商報告第三季度每股收益（EPS）為 1.30 美元，符合分析師的共識預期 1.30 美元。該公司在該季度的收入為 113.7 億美元，而分析師預期為 114 億美元。雅培的股本回報率為 17.60%，淨利潤率為 31.88%。該公司的季度收入較去年同期增長 6.9%。在去年同期，該公司每股收益為 1.21 美元。雅培已將其 2025 財年的指導目標設定為 5.120-5.180 EPS。研究分析師預測雅培在當前財年將發佈 5.14 的每股收益。</p>
<h2>雅培增加股息</h2>
<p>該公司還最近宣佈了一項季度股息，將於 2 月 13 日（星期五）支付。1 月 15 日（星期四）登記的股東將獲得每股 0.63 美元的股息。該股息的除息日為 1 月 15 日（星期四）。這比雅培之前的季度股息 0.59 美元有所增加。這相當於每年 2.52 美元的股息，股息收益率為 2.0%。雅培的股息支付比率目前為 29.57%。</p>
<h2>分析師評級變動</h2>
<ul>
<li>為什麼雅培是 2025 年第二季度的買入：增長與收益</li>
</ul>
<p>一些研究分析師最近對 ABT 股票發表了評論。富國銀行將雅培的股票目標價從 142.00 美元上調至 146.00 美元，並在 10 月 16 日的研究報告中給予該公司 “增持” 評級。Weiss Ratings 在週一重申了對雅培股票的 “買入（b-）” 評級。Evercore ISI 將雅培的股票目標價從 144.00 美元下調至 142.00 美元，並在 10 月 15 日的研究報告中對該股票給予 “跑贏大盤” 評級。Raymond James Financial 將雅培的股票目標價從 141.00 美元上調至 146.00 美元，並在 10 月 16 日的研究報告中給予該公司 “跑贏大盤” 評級。最後，加拿大皇家銀行在 10 月 16 日的報告中重申了 “跑贏大盤” 評級，並對雅培的股票設定了 147.00 美元的目標價。兩位分析師給予該股票 “強烈買入” 評級，十七位分析師給予 “買入” 評級，四位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 147.00 美元。</p>
<p><strong>獲取我們最新的雅培股票分析</strong></p>
<h2>雅培公司簡介</h2>
<p>（免費報告）</p>
<p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的阿博特公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，業務涵蓋多個領域，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
<p>在診斷方面，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>什麼是股息之王？</li>
<li>MarketBeat 週迴顧 – 12/15 - 12/19</li>
<li>股票中的跳空上漲意味着什麼？如何利用跳空</li>
<li>耐克盈利超預期，但在中國市場面臨挑戰並遭遇關税</li>
<li>在 52 周高點盈利交易股票</li>
<li>人工智能熱潮是泡沫嗎？這兩隻股息股票表示不是</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

<p>Meadowbrook Wealth Management LLC 在第三季度收購了雅培的新股份，購買了 9,270 股，價值約為 1,242,000 美元。這項投資佔 Meadowbrook 投資組合的 1.3%。雅培的股票由 75.18% 的機構投資者和對沖基金持有。該公司最近報告了第三季度每股收益為 1.30 美元，並將季度股息提高至每股 0.63 美元。分析師給予了積極的評級，目標價格範圍在 142 美元到 147 美元之間</p>

<p>Meadowbrook Wealth Management LLC bought a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,270 shares of the healthcare product maker's stock, valued at approximately $1,242,000. Abbott Laboratories comprises approximately 1.3% of Meadowbrook Wealth Management LLC's investment portfolio, making the stock its 19th biggest position.</p>
<div class="lb-trans"><p>梅多布魯克財富管理公司在第三季度購買了雅培（NYSE:ABT - 免費報告）的一項新股份，根據該公司在最近向證券交易委員會提交的 13F 表格。該基金購買了 9,270 股該醫療產品製造商的股票，價值約為 1,242,000 美元。雅培在梅多布魯克財富管理公司的投資組合中佔約 1.3%，使其成為該公司第 19 大持倉。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超預期後的新底部</li>
</ul>
</div><p>Other hedge funds also recently modified their holdings of the company. IMG Wealth Management Inc. lifted its stake in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock valued at $26,000 after buying an additional 167 shares during the period. Anfield Capital Management LLC raised its holdings in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. Delos Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories during the second quarter worth $32,000. Curio Wealth LLC grew its position in shares of Abbott Laboratories by 15,250.0% in the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after purchasing an additional 305 shares during the period. Finally, Pineridge Advisors LLC lifted its position in Abbott Laboratories by 34.6% during the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock worth $43,000 after buying an additional 81 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他對沖基金最近也調整了對該公司的持股。IMG Wealth Management Inc. 在第二季度將其在雅培的股份增加了 759.1%。IMG Wealth Management Inc. 目前擁有 189 股該醫療產品製造商的股票，價值 26,000 美元，此前在該期間又購買了 167 股。Anfield Capital Management LLC 在第二季度將其在雅培的持股增加了 81.3%。Anfield Capital Management LLC 目前擁有 232 股該醫療產品製造商的股票，價值 32,000 美元，此前在上個季度又收購了 104 股。Delos Wealth Advisors LLC 在第二季度收購了雅培的新股份，價值 32,000 美元。Curio Wealth LLC 在第二季度將其在雅培的持倉增加了 15,250.0%。Curio Wealth LLC 目前擁有 307 股該醫療產品製造商的股票，價值 42,000 美元，此前在該期間又購買了 305 股。最後，Pineridge Advisors LLC 在第二季度將其在雅培的持倉增加了 34.6%。Pineridge Advisors LLC 目前擁有 315 股該醫療產品製造商的股票，價值 43,000 美元，此前在該期間又購買了 81 股。75.18% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Abbott Laboratories Trading Up 0.3%</h2>
<div class="lb-trans"><h2>雅培股票上漲 0.3%</h2>
</div><p>NYSE:ABT opened at $125.45 on Friday. The business's 50-day moving average is $126.77 and its two-hundred day moving average is $130.27. The firm has a market capitalization of $218.13 billion, a PE ratio of 15.72, a price-to-earnings-growth ratio of 2.28 and a beta of 0.72. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24.</p>
<div class="lb-trans"><p>NYSE:ABT 週五開盤價為 125.45 美元。該公司的 50 日移動平均線為 126.77 美元，200 日移動平均線為 130.27 美元。該公司的市值為 2181.3 億美元，市盈率為 15.72，市盈增長比率為 2.28，貝塔值為 0.72。雅培的 12 個月低點為 110.86 美元，12 個月高點為 141.23 美元。該公司的債務與股本比率為 0.23，流動比率為 1.70，速動比率為 1.24。</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培十月股價暴跌是買入信號</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.30. The business had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company's revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近於 10 月 15 日發佈了其財報。該醫療產品製造商報告第三季度每股收益（EPS）為 1.30 美元，符合分析師的共識預期 1.30 美元。該公司在該季度的收入為 113.7 億美元，而分析師預期為 114 億美元。雅培的股本回報率為 17.60%，淨利潤率為 31.88%。該公司的季度收入較去年同期增長 6.9%。在去年同期，該公司每股收益為 1.21 美元。雅培已將其 2025 財年的指導目標設定為 5.120-5.180 EPS。研究分析師預測雅培在當前財年將發佈 5.14 的每股收益。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. Abbott Laboratories's dividend payout ratio is presently 29.57%.</p>
<div class="lb-trans"><p>該公司還最近宣佈了一項季度股息，將於 2 月 13 日（星期五）支付。1 月 15 日（星期四）登記的股東將獲得每股 0.63 美元的股息。該股息的除息日為 1 月 15 日（星期四）。這比雅培之前的季度股息 0.59 美元有所增加。這相當於每年 2.52 美元的股息，股息收益率為 2.0%。雅培的股息支付比率目前為 29.57%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼雅培是 2025 年第二季度的買入：增長與收益</li>
</ul>
</div><p>A number of research analysts have recently commented on ABT shares. Wells Fargo &amp; Company upped their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, October 16th. Weiss Ratings restated a &#34;buy (b-)&#34; rating on shares of Abbott Laboratories in a report on Monday. Evercore ISI cut their price target on shares of Abbott Laboratories from $144.00 to $142.00 and set an &#34;outperform&#34; rating on the stock in a research note on Wednesday, October 15th. Raymond James Financial boosted their price objective on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, October 16th. Finally, Royal Bank Of Canada reiterated an &#34;outperform&#34; rating and issued a $147.00 target price on shares of Abbott Laboratories in a report on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $147.00.</p>
<div class="lb-trans"><p>一些研究分析師最近對 ABT 股票發表了評論。富國銀行將雅培的股票目標價從 142.00 美元上調至 146.00 美元，並在 10 月 16 日的研究報告中給予該公司 “增持” 評級。Weiss Ratings 在週一重申了對雅培股票的 “買入（b-）” 評級。Evercore ISI 將雅培的股票目標價從 144.00 美元下調至 142.00 美元，並在 10 月 15 日的研究報告中對該股票給予 “跑贏大盤” 評級。Raymond James Financial 將雅培的股票目標價從 141.00 美元上調至 146.00 美元，並在 10 月 16 日的研究報告中給予該公司 “跑贏大盤” 評級。最後，加拿大皇家銀行在 10 月 16 日的報告中重申了 “跑贏大盤” 評級，並對雅培的股票設定了 147.00 美元的目標價。兩位分析師給予該股票 “強烈買入” 評級，十七位分析師給予 “買入” 評級，四位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 147.00 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的雅培股票分析</strong></p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的阿博特公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，業務涵蓋多個領域，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在診斷方面，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>What is a Dividend King?</li>
<li>MarketBeat Week in Review – 12/15 - 12/19</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>什麼是股息之王？</li>
<li>MarketBeat 週迴顧 – 12/15 - 12/19</li>
<li>股票中的跳空上漲意味着什麼？如何利用跳空</li>
<li>耐克盈利超預期，但在中國市場面臨挑戰並遭遇關税</li>
<li>在 52 周高點盈利交易股票</li>
<li>人工智能熱潮是泡沫嗎？這兩隻股息股票表示不是</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Meadowbrook Wealth Management LLC 收購雅培實驗室的新股份 $ABT